Do cardiologists from the AFFIRM generation treat AF less aggressively than the EAST-AFNET generation? Bob Harrington and Jonathan Piccini discuss this and upcoming trials on atrial fibrillation.

This podcast is intended for healthcare professionals only.

To read a transcript or to comment, visit:

https://www.medscape.com/author/bob-harrington

A Comparison of Rate Control and Rhythm Control in Patients with Atrial Fibrillation (AFFIRM)

https://www.nejm.org/doi/full/10.1056/NEJMoa021328

Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4)

https://www.nejm.org/doi/10.1056/NEJMoa2019422

Early AF Rhythm-Control Advantage Climbs With Comorbidity Burden: EAST-AFNET4

https://www.medscape.com/viewarticle/979627

Early Dronedarone Versus Usual Care to Improve Outcomes in Persons With Newly Diagnosed Atrial Fibrillation (CHANGE-AFIB)

https://clinicaltrials.gov/ct2/show/NCT05130268

Generalizability of the EAST‐AFNET 4 Trial: Assessing Outcomes of Early Rhythm‐Control Therapy in Patients With Atrial Fibrillation

https://doi.org/10.1161/JAHA.121.024214

Early Rhythm Control Therapy for Atrial Fibrillation in Low-Risk Patients

A Nationwide Propensity Score–Weighted Study

https://doi.org/10.7326/M21-4798

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology

https://www.medscape.com/twic

Questions or feedback, please contact

news@medscape.net